Analyst: Eli Lilly considers Alzheimer's submission after phase II

Eli Lilly is so enthusiastic about its potential Alzheimer's treatment donanemab that the firm is ready to submit the drug for evaluation on the basis of data coming from two phase II trials.

Photo: Mike Blake/REUTERS / X00030

Drug candidate donanemab might potentially become the second Alzheimer's drug to be submitted to the US Food and Drug Administration within a short time span.

After a year-long standstill in the development of new treatments, US firm Biogen sent the drug aducanumab to be evaluated by the FDA in 2020, and now, soon after, another US pharmaceutical company – Eli Lilly – might also submit an application for marketing its drug donanemab, deems financial analyst house Cowen after meeting Eli Lilly's group of executives, writes finance media Barrons.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs